Toulouse and Geneva, December 22, 2016 Genticel and Genkyotex Announce Intention to Enter into Strategic Combination. Genkyotex is a pioneer in discovery and development of NOX therapeutics. Transaction would create ...

The ANGEL-MS extension study will offer the 260 patients enrolled in the on-going Phase IIb CHANGE-MS study the opportunity to continue their treatment for an additional two years and will provide additional efficacy and ...